secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001558370-21-015885
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.01, 2.02, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala acquires Combangio for $5M cash, $16.1M stock; board adds Blumenkranz
--------------------------------------------------------------------------

- Upfront payment $5.0M cash + 7,788,667 shares (~$16.1M) representing 11.9% of Kala's outstanding.
- Contingent consideration up to $105M in milestones plus tiered mid-to-high single-digit royalties on KPI-012 sales.
- Board appoints Mark Blumenkranz, former Combangio board member, as Class II director; receives option for 42,000 shares.
- Kala terminates Watertown lease, receives $2M termination consideration; HQ moves to Arlington, MA; outsources lab activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021015885/0001558370-21-015885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837021015885/kala-20211112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-015885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer